Psoriatic Arthritis
Conference Coverage
ILD risk elevated in RA, PsA after starting biologic or targeted synthetic DMARDs
The risk for interstitial lung disease in patients with PsA during the first 5 years after starting a biologic or targeted synthetic DMARD was...
News from the FDA/CDC
FDA approves Yuflyma as ninth adalimumab biosimilar
The manufacturer Celltrion is also seeking an interchangeability designation from the FDA, tentatively expected in the fourth quarter of 2024.
News from the FDA/CDC
FDA approves autoinjector pen for Humira biosimilar, Cyltezo
The drug will be commercially available on July 1, 2023.
Conference Coverage
MACE, VTE rates compared between TNF and JAK inhibitors for AxSpA and PsA
Patients with axial spondyloarthritis and psoriatic arthritis who used JAK inhibitors did not have higher risk of myocardial infarction or stroke...
From the Journals
Brepocitinib shows promise for psoriatic arthritis patients
Data from a phase 2b trial showed superior symptom reduction, compared with placebo, by 1 year.
Feature
Axial spondyloarthritis versus axial psoriatic arthritis: Different entities?
Features of axial psoriatic arthritis and axial spondyloarthritis overlap, but whether they’re different diseases or on the same spectrum is...
Latest News
COVID-19 and psoriasis: Is there a link?
“Infection with COVID-19 has been associated with flares of guttate and pustular psoriasis, and even psoriasis that affects 100% of the skin.”
Conference Coverage
Meta-analysis examines cancer risk concern for JAK inhibitors
Although no increased cancer risk was seen vs. methotrexate or placebo, Janus kinase inhibitors were associated with a higher cancer risk than...
Latest News
NPF provides guidance for virtual psoriasis visits
A National Psoriasis Foundation position paper addresses ongoing management of psoriatic disease via telemedicine.
Latest News
New 46-week PsA data released for IL-17A inhibitor izokibep
Long-term data build on statistically significant improvements demonstrated at 16 weeks across key measures of joint pain, psoriasis, and...
Feature
Biosimilars and patients: Discussions should address safety, cost, and anxiety about change
Physicians can respond to pushback from patients on switching to a biosimilar by offering resources and discussing options for both biosimilar and...